TrialThe British journal of dermatology2019

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.

K A Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.